Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: Initial experience

Radiology

Volumn 234, Issue 3, 2005, Pages 851-859

  Johnson, Nathan A ^a   Jahng, Geon Ho ^a   Weiner, Michael W ^a   Miller, Bruce L ^a   Chui, Helena C ^a   Jagust, William J ^a   Gorno Tempini, Maria L ^a   Schuff, Norbert ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; BRAIN PERFUSION; BRAIN SIZE; CINGULATE GYRUS; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SPIN LABELING;

AGED; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BRAIN; CEREBROVASCULAR CIRCULATION; COGNITION DISORDERS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; SPIN LABELS; TECHNETIUM TC 99M EXAMETAZIME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 13844298168     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2343040197     Document Type: Article

References (45)

1. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997; 18:351-357.
2. Braak H, Braak E. Evolution of neuronal changes in the course of Alzheimer's disease. J Neural Transm Suppl 1998; 53:127-140.
3. Tariot PN, Federoff HJ. Current treatment for Alzheimer disease and future prospects. Alzheimer Dis Assoc Disord 2003; 17(suppl4):S105-S113.
4. Mielke R, Kessler J, Szelies B, Herholz K, Wienhard K, Heiss WD. Normal and pathological aging: findings of positron-emission-tomography. J Neural Transm 1998; 105:821-837.
5. Jagust WJ. Neuroimaging in dementia. Neurol Clin 2000; 18:885-902.
6. Petrella JR, Coleman RE, Doraiswamy PM. Neuroimaging and early diagnosis of Alzheimer disease: a look to the future. Radiology 2003; 226:315-336.
7. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 1995; 273:942-947.
8. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334:752-758.
9. Johnson KA, Lopera F, Jones K, et al. Presenilin-1-associated abnormalities in regional cerebral perfusion. Neurology 2001; 56:1545-1551.
10. Kennedy AM, Frackowiak RS, Newman SK, et al. Deficits in cerebral glucose metabolism demonstrated by positron emission tomography in individuals at risk of familial Alzheimer's disease. Neurosci Lett 1995; 186:17-20.
11. Johnson KA, Jones K, Holman BL, et al. Preclinical prediction of Alzheimer's disease using SPECT. Neurology 1998; 50:1563-1571.
12. Kogure D, Matsuda H, Ohnishi T, et al. Longitudinal evaluation of early Alzheimer's disease using brain perfusion SPECT. J Nucl Med 2000; 41:1155-1162.
13. Johnson KA, Albert MS. Perfusion abnormalities in prodromal AD. Neurobiol Aging 2000; 21:289-292.
14. El Fakhri G, Kijewski MF, Johnson KA, et al. MRI-guided SPECT perfusion measures and volumetric MRI in prodromal Alzheimer disease. Arch Neurol 2003; 60:1066-1072.
15. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. NeuroReport 2001; 12:851-855.
16. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC. Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60:1374-1377.
17. Huang C, Wahlund LO, Almkvist O, et al. Voxel- and VOI-based analysis of SPECT CBF in relation to clinical and psychological heterogeneity of mild cognitive impairment. Neuroimage 2003; 19:1137-1144.
18. Roberts DA, Detre JA, Bolinger L, Insko EK, Leigh JJ. Quantitative magnetic resonance imaging of human brain perfusion at 1.5 T using steady-state inversion of arterial water. Proc Natl Acad Sci USA 1994; 91:33-37.
19. Jueptner M, Weiller C. Review: does measurement of regional cerebral blood flow reflect synaptic activity? implications for PET and fMRI. Neuroimage 1995; 2:148-156.
20. Detre JA, Alsop DC. Perfusion magnetic resonance imaging with continuous arterial spin labeling: methods and clinical applications in the central nervous system. Eur J Radiol 1999; 30:115-124.
21. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000; 47:93-100.
22. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998; 50:1585-1593.
23. Meltzer CC, Zubieta JK, Brandt J, Tune LE, Mayberg HS, Frost JJ. Regional hypometabolism in Alzheimer's disease as measured by positron emission tomography after correction for effects of partial volume averaging. Neurology 1996; 47:454-461.
24. Meltzer CC, Cantwell MN, Greer PJ, et al. Does cerebral blood flow decline in healthy aging? a PET study with partial-volume correction. J Nucl Med 2000; 41:1842-1848.
25. Matsuda H, Kanetaka H, Ohnishi T, et al. Brain SPET abnormalities in Alzheimer's disease before and after atrophy correction. Eur J Nucl Med Mol Imaging 2002; 29:1502-1505.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198.
27. Delis DC, Kramer JH, Kaplan E, Ober BA. California Verbal Learning Test (CVLT). San Antonio, Tex: Psychological Corporation, 2000.
28. Lezak MD. Neuropsychologlcal assessment. 3rd ed. New York, NY: Oxford University Press, 1995.
29. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43:2412-2414.
30. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol 1982; 37:323-329.
31. Criteria for the clinical diagnosis of Alzheimer's disease: excerpts from the NINCDS-ADRDA Work Group report. J Am Geriatr Soc 1985; 33:2-3.
32. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999; 56:303-308.
33. Jahng GH, Zhu XP, Matson GB, Weiner MW, Schuff N. Improved perfusion-weighted MRI by a novel double inversion with proximal labeling of both tagged and control acquisitions. Magn Reson Med 2003; 49:307-314.
34. Luh WM, Wong EC, Bandettini PA, Hyde JS. QUIPSS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magn Reson Med 1999; 41:1246-1254.
35. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS. A voxel-based morphometric study of aging in 465 normal adult human brains. Neuroimage 2001; 14:21-36.
36. Meltzer CC, Leal JP, Mayberg HS, Wagner HN Jr, Frost JJ. Correction of PET data for partial volume effects in human cerebral cortex by MR imaging. J Comput Assist Tomogr 1990; 14:561-570.
37. Muller-Gartner HW, Links JM, Prince JL, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab 1992; 12:571-583.
38. Salmond CH, Ashburner J, Vargha-Khadem F, Gadian DG, Friston KJ. Detecting bilateral abnormalities with voxel-based morphometry. Hum Brain Mapp 2000; 11:223-232.
39. Bradley KM, O'Sullivan VT, Soper ND, et al. Cerebral perfusion SPECT correlated with Braak pathological stage in Alzheimer's disease. Brain 2002; 125:1772-1781.
40. Lee YC, Liu RS, Liao YC, et al. Statistical parametric mapping of brain SPECT perfusion abnormalities in patients with Alzheimer's disease. Eur Neurol 2003; 49:142-145.
41. Matsuda H, Kitayama N, Ohnishi T, et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J Nucl Med 2002; 43:304-311.
42. Meguro K, LeMestric C, Landeau B, Desgranges B, Eustache F, Baron JC. Relations between hypometabolism in the posterior association neocortex and hippocampal atrophy in Alzheimer's disease: a PET/ MRI correlative study. J Neurol Neurosurg Psychiatry 2001; 71:315-321.
43. Varma AR, Adams W, Lloyd JJ, et al. Diagnostic patterns of regional atrophy on MRI and regional cerebral blood flow change on SPECT in young onset patients with Alzheimer's disease, frontotemporal dementia and vascular dementia. Acta Neurol Scand 2002; 105:261-269.
44. Chetelat G, Desgranges B, de la Sayette V, et al. Dissociating atrophy and hypometabolism impact on episodic memory in mild cognitive impairment. Brain 2003; 126:1955-1967.
45. Wolf H, Jelic V, Gertz HJ, Nordberg A, Julin P, Wahlund LO. A critical discussion of the role of neuroimaging in mild cognitive impairment. Acta Neurol Scand Suppl 2003; 179:52-76.